高危人群肝细胞癌筛查的利与弊:系统回顾与荟萃分析

Jichun Yang , Zhirong Yang , Xueyang Zeng , Shuqing Yu , Le Gao , Yu Jiang , Feng Sun
{"title":"高危人群肝细胞癌筛查的利与弊:系统回顾与荟萃分析","authors":"Jichun Yang ,&nbsp;Zhirong Yang ,&nbsp;Xueyang Zeng ,&nbsp;Shuqing Yu ,&nbsp;Le Gao ,&nbsp;Yu Jiang ,&nbsp;Feng Sun","doi":"10.1016/j.jncc.2023.02.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The incidence and mortality of hepatocellular carcinoma (HCC) have been increasing around the world. Current guidelines recommend HCC screening in high-risk population. However, the strength of evidence of benefits and harms of HCC screening to support the recommendation was unclear. The objective is to systematically synthesize current evidence on the benefits and harms of HCC screening.</p></div><div><h3>Methods</h3><p>We searched PubMed and nine other databases until August 20, 2021. We included cohort studies and RCTs that compared the benefits and harms of screening and non-screening in high-risk population of HCC. Case series studies that reported harms of HCC screening were also included. Pooled risk ratio (RR), according to HCC screening status, was calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using head-to-head meta-analysis. The harmful outcomes (e.g., proportion of physiological harms provided by non-comparative studies were pooled by prevalence of meta-analysis. Analysis on publication bias and quality of life, subgroup analysis, and sensitivity analysis were also conducted.</p></div><div><h3>Results</h3><p>We included 70 studies, including four random clinical trials (RCTs), 63 cohort studies,three case series studies. The meta-analysis of RCTs showed HCC screening was significantly associated with reduced HCC mortality (RR [risk ratio], 0.73 [95% CI, 0.56–0.96]; <em>I</em><sup>2</sup> = 75.1%), prolonged overall survival rates (1-year, RR, 1.72 [95% CI, 1.13–2.61]; <em>I</em><sup>2</sup> = 72.5%; 3-year, RR, 2.86 [95% CI, 1.78–4.58]; <em>I</em><sup>2</sup> = 10.1%; and 5-year, RR, 2.76 [95% CI, 1.37–5.54]; <em>I</em><sup>2</sup> = 28.3%), increased proportion of early HCC detection (RR, 2.68 [95% CI, 1.77–4.06]; <em>I</em><sup>2</sup> = 50.4%). Similarly, meta-analysis of cohort studies indicated HCC screening was more effective than non-screening. However, pooled proportion of physiological harms was 16.30% (95% CI: 8.92%–23.67%) and most harms were of a mild to moderate severity.</p></div><div><h3>Conclusion</h3><p>The existing evidence suggests HCC screening is more effective than non-screening in high-risk population. However, harms of screening should not be ignored.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 3","pages":"Pages 175-185"},"PeriodicalIF":7.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis\",\"authors\":\"Jichun Yang ,&nbsp;Zhirong Yang ,&nbsp;Xueyang Zeng ,&nbsp;Shuqing Yu ,&nbsp;Le Gao ,&nbsp;Yu Jiang ,&nbsp;Feng Sun\",\"doi\":\"10.1016/j.jncc.2023.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The incidence and mortality of hepatocellular carcinoma (HCC) have been increasing around the world. Current guidelines recommend HCC screening in high-risk population. However, the strength of evidence of benefits and harms of HCC screening to support the recommendation was unclear. The objective is to systematically synthesize current evidence on the benefits and harms of HCC screening.</p></div><div><h3>Methods</h3><p>We searched PubMed and nine other databases until August 20, 2021. We included cohort studies and RCTs that compared the benefits and harms of screening and non-screening in high-risk population of HCC. Case series studies that reported harms of HCC screening were also included. Pooled risk ratio (RR), according to HCC screening status, was calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using head-to-head meta-analysis. The harmful outcomes (e.g., proportion of physiological harms provided by non-comparative studies were pooled by prevalence of meta-analysis. Analysis on publication bias and quality of life, subgroup analysis, and sensitivity analysis were also conducted.</p></div><div><h3>Results</h3><p>We included 70 studies, including four random clinical trials (RCTs), 63 cohort studies,three case series studies. The meta-analysis of RCTs showed HCC screening was significantly associated with reduced HCC mortality (RR [risk ratio], 0.73 [95% CI, 0.56–0.96]; <em>I</em><sup>2</sup> = 75.1%), prolonged overall survival rates (1-year, RR, 1.72 [95% CI, 1.13–2.61]; <em>I</em><sup>2</sup> = 72.5%; 3-year, RR, 2.86 [95% CI, 1.78–4.58]; <em>I</em><sup>2</sup> = 10.1%; and 5-year, RR, 2.76 [95% CI, 1.37–5.54]; <em>I</em><sup>2</sup> = 28.3%), increased proportion of early HCC detection (RR, 2.68 [95% CI, 1.77–4.06]; <em>I</em><sup>2</sup> = 50.4%). Similarly, meta-analysis of cohort studies indicated HCC screening was more effective than non-screening. However, pooled proportion of physiological harms was 16.30% (95% CI: 8.92%–23.67%) and most harms were of a mild to moderate severity.</p></div><div><h3>Conclusion</h3><p>The existing evidence suggests HCC screening is more effective than non-screening in high-risk population. However, harms of screening should not be ignored.</p></div>\",\"PeriodicalId\":73987,\"journal\":{\"name\":\"Journal of the National Cancer Center\",\"volume\":\"3 3\",\"pages\":\"Pages 175-185\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Center\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667005423000066\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005423000066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

目的肝细胞癌(HCC)的发病率和死亡率在世界范围内呈上升趋势。目前的指南建议在高危人群中进行HCC筛查。然而,支持这一建议的HCC筛查的益处和危害的证据强度尚不清楚。目的是系统地综合目前关于HCC筛查利弊的证据。方法检索PubMed等9个数据库,截止到2021年8月20日。我们纳入了队列研究和随机对照试验,比较了HCC高危人群中筛查和非筛查的益处和危害。报告HCC筛查危害的病例系列研究也包括在内。根据HCC筛查状态,使用头对头meta分析计算每个获益结果(如HCC死亡率、生存率、早期HCC比例)的合并风险比(RR)。有害结果(例如,由非比较研究提供的生理危害的比例)通过荟萃分析的流行程度汇总。并进行发表偏倚与生活质量分析、亚组分析和敏感性分析。结果纳入70项研究,包括4项随机临床试验(RCTs)、63项队列研究、3项病例系列研究。随机对照试验的荟萃分析显示,HCC筛查与HCC死亡率降低显著相关(RR[危险比],0.73 [95% CI, 0.56-0.96];I2 = 75.1%),延长总生存率(1年,RR, 1.72 [95% CI, 1.13-2.61];i2 = 72.5%;3年,RR, 2.86 [95% CI, 1.78-4.58];i2 = 10.1%;5年,RR为2.76 [95% CI, 1.37 ~ 5.54];I2 = 28.3%),早期HCC检出率增高(RR, 2.68 [95% CI, 1.77 ~ 4.06];i2 = 50.4%)。同样,队列研究的荟萃分析表明,HCC筛查比非筛查更有效。然而,生理危害的合并比例为16.30% (95% CI: 8.92%-23.67%),大多数危害为轻至中度。结论在高危人群中,HCC筛查比不筛查更有效。然而,筛查的危害也不容忽视。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis

Objective

The incidence and mortality of hepatocellular carcinoma (HCC) have been increasing around the world. Current guidelines recommend HCC screening in high-risk population. However, the strength of evidence of benefits and harms of HCC screening to support the recommendation was unclear. The objective is to systematically synthesize current evidence on the benefits and harms of HCC screening.

Methods

We searched PubMed and nine other databases until August 20, 2021. We included cohort studies and RCTs that compared the benefits and harms of screening and non-screening in high-risk population of HCC. Case series studies that reported harms of HCC screening were also included. Pooled risk ratio (RR), according to HCC screening status, was calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using head-to-head meta-analysis. The harmful outcomes (e.g., proportion of physiological harms provided by non-comparative studies were pooled by prevalence of meta-analysis. Analysis on publication bias and quality of life, subgroup analysis, and sensitivity analysis were also conducted.

Results

We included 70 studies, including four random clinical trials (RCTs), 63 cohort studies,three case series studies. The meta-analysis of RCTs showed HCC screening was significantly associated with reduced HCC mortality (RR [risk ratio], 0.73 [95% CI, 0.56–0.96]; I2 = 75.1%), prolonged overall survival rates (1-year, RR, 1.72 [95% CI, 1.13–2.61]; I2 = 72.5%; 3-year, RR, 2.86 [95% CI, 1.78–4.58]; I2 = 10.1%; and 5-year, RR, 2.76 [95% CI, 1.37–5.54]; I2 = 28.3%), increased proportion of early HCC detection (RR, 2.68 [95% CI, 1.77–4.06]; I2 = 50.4%). Similarly, meta-analysis of cohort studies indicated HCC screening was more effective than non-screening. However, pooled proportion of physiological harms was 16.30% (95% CI: 8.92%–23.67%) and most harms were of a mild to moderate severity.

Conclusion

The existing evidence suggests HCC screening is more effective than non-screening in high-risk population. However, harms of screening should not be ignored.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
70 days
期刊最新文献
Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study. Osteoimmunology in bone malignancies: a symphony with evil. Disseminated tumor cells in bone marrow as predictive classifiers for small cell lung cancer patients. Editorial Board TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1